Site menu:
Reduction by 68 to 77%
of Urinary Infections
Double Blind versus placebo (2008, July) !
The purpose of this study is to prove the urinary comfort improvment by using UTIrose™.
In-vivo
study has started to confirm
the Urinary comfort improvement (Prevention of urinary tract
infections, Limitation of risks of infections with repetition) and so
get the official claim as a preventive product.Burgundy has conducted this in-vivo study on 60- 90 people, taking 200mg of UTIrose™ or 200mg of placebo (maltodextrine). This study has been running since January 2008 until July 2008, meaning 168 days.
- 77% reduction of the urinary infection after 168 days (ie. 24 weeks) with UTIrose™.
- 68% reduction with UTIrose™ Premium
The intermediate resultats after 84 days shows a decrease of the urinary infections by ca. 60%, with a very-low p-value (p=0.001).
Placebo : both results after 84 or 168 days are with a non significant "Student value" (p>5%), respectively at -20% and -38%.
What means the p-value ? also named Student value, the p-value gives the significancy of the results. A value over 5% (p>0,05) is non significant. A value from 1% to 5% is significant. A value = 0,1% (p=0,001) is very significant, and even more when below 0,001.
It just a new confirmation of the efficiency of UTIrose, much better than any other plant extracts that we checked.
Also checked in the study performed by Burgundy : urinary discomfort, mucous membranes, and appreciation of the global urinary comfort.
Criteria of inclusion for the recruitment of the volunteers. Medical examination after 84 and 168 days.
- women from 18 to 55 years old
- 3 groups of 20 to 30 women (placebo, 200mg UTIrose regular, 200mg UTIrose premium)
- Women complaining of urinary discomfort, having urinary infections with repetition
- Women having more than 8 episodes per 12 months. The average of the patients of our study is at 9,68 episodes per year.